Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.50 |
| ▸ | BCHE | P06276 | 10/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945832 | 1.00 | ACHE (0.50) | ACHEBCHEFAAHLMNAMARK4 | |
| Cadaverine Tartrate SCHEMBL3946120 | 0.94 | ACHE (0.57) | ACHEBCHEFAAHLMNAMARK4 | |
| SCHEMBL3458221 | 0.77 | ACHE (0.59) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL1195514 | 0.77 | LMNA (0.78) | LMNAALDH1A1 | |
| SCHEMBL16103423 | 0.76 | ACHE (0.48) | ACHEBCHEFAAHMARK4ALDH1A1 | |
| SCHEMBL16103422 | 0.76 | ACHE (0.48) | ACHEBCHEFAAHMARK4ALDH1A1 | |
| SCHEMBL951920 | 0.75 | LMNA (0.56) | LMNAPPARGALDH1A1 | |
| SCHEMBL6183303 | 0.75 | PTGES (0.62) | LMNAPTGESPPARGALDH1A1 | |
| SCHEMBL3891099 | 0.74 | ACHE (0.52) | ACHEBCHEFAAHMARK4ALDH1A1 | |
| SCHEMBL11142759 | 0.73 | LMNA (0.64) | LMNAPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637713-B2 | Process for preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | claimed |
| US-8415508-B2 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | claimed |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| US-7544840-B2 | Method of production of (−)-(S)-3-[1-(dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate | ZENTIVA, A.S. (CZ) | 2009-06-09 | — | — | US | claimed |
| EP-1556338-B1 | A METHOD OF PRODUCTION OF (-)-(S)-3- [1-(DIMETHYLAMINO)ETHYL] PHENYL-N-ETHYL-N-METHYLCARBAMATE | ZENTIVA AS (CZ) | 2008-05-14 | — | — | EP | claimed |
| US-20060122417-A1 | Method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate | ZENTIVA, A.S. (CZ) | 2006-06-08 | — | — | US | claimed |
| EP-0952826-B1 | IDEBENONE CONTAINING COMBINATION AGENT FOR TREATING ALZHEIMER'S DISEASE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-11-14 | — | — | EP | claimed |
| US-7544840-B2 | Method of production of (−)-(S)-3-[1-(dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate | ZENTIVA, A.S. (CZ) | 2009-06-09 | — | — | US | disclosed |
| US-7544840-B2 | Method of production of (−)-(S)-3-[1-(dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate | ZENTIVA, A.S. (CZ) | 2009-06-09 | — | — | US | disclosed |
| EP-1556338-B1 | A METHOD OF PRODUCTION OF (-)-(S)-3- [1-(DIMETHYLAMINO)ETHYL] PHENYL-N-ETHYL-N-METHYLCARBAMATE | ZENTIVA AS (CZ) | 2008-05-14 | — | — | EP | disclosed |
| US-20060122417-A1 | Method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate | ZENTIVA, A.S. (CZ) | 2006-06-08 | — | — | US | disclosed |
| US-20060122417-A1 | Method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate | ZENTIVA, A.S. (CZ) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | SPR, ACHE, QDPR | ACHE 2/4885BCHE 33/4885FAAH 760/4885 |
| US-20060122417-A1 | Method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate | ACHE, BCHE, CHRNA7 | ACHE 1/4885BCHE 2/4885FAAH 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.